^
    2d
    Bergenin Suppresses Glycolysis and Malignant Progression in Breast Cancer via the IGF1R-MAPK Signaling Pathway. (PubMed, Ann Clin Lab Sci)
    Ber suppresses glycolysis and malignant progression in BC through modulation of the IGF1R-MAPK signaling pathway.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • IGF1R (Insulin-like growth factor 1 receptor) • PHGDH (Phosphoglycerate Dehydrogenase) • KDM5B (Lysine Demethylase 5B) • LGALS9 (Galectin 9) • PKM (Pyruvate Kinase M1/2)
    5d
    Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin. (PubMed, Front Endocrinol (Lausanne))
    We found that IGF-1 stimulation increased MDA-MB-231 TNBC adhesion, which was reversed by the IGF1R tyrosine kinase inhibitor BMS-754807 and the ligand-dependent receptor internalization inhibitor dansylcadaverine...This model is supported further by our finding that treatment of MDA-MB-231 cells with dansylcadaverine, which inhibits ligand-mediated receptor internalization, blocked the effect of IGF-1 on adhesion. These findings further elucidate IGF1R function during breast cancer metastasis by modulating cell adherence.
    Journal
    |
    IGF1 (Insulin-like growth factor 1)
    |
    BMS-754807
    8d
    Treatment of Chronic Thyroid Eye Disease With MHB018A (clinicaltrials.gov)
    P3, N=135, Not yet recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P3 trial
    8d
    Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=219, Not yet recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P3 trial
    8d
    Integrative analysis of lncRNAs associated with disulfidptosis-related genes for prognostic risk evaluation and tumor immune microenvironment assessment in laryngeal squamous cell carcinoma. (PubMed, Hum Cell)
    Exploratory in silico drug-response analyses identified differential predicted responses to entinostat, linsitinib, and VE-822 according to risk status and DUBR expression. This internally validated signature may support exploratory prognostic risk stratification of LSCC within the analyzed TCGA-derived cohort and may highlight DUBR as a candidate molecule for further biological investigation. Further validation in independent external cohorts and dedicated disulfidptosis functional assays is required before these findings can be considered generalizable.
    Journal
    |
    TLN1 (Talin 1) • METTL3 (Methyltransferase Like 3)
    |
    berzosertib (M6620) • Jingzhuda (entinostat) • linsitinib (ASP7487)
    8d
    Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study (clinicaltrials.gov)
    P3, N=84, Not yet recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P3 trial
    12d
    Precision Management of Autoimmune Ocular Complications: Th17 Mechanisms and Therapeutic Innovations. (PubMed, Exp Eye Res)
    Therapeutically, anti-TNF-α monoclonal antibodies, teprotumumab, and avacopan target critical pathways and improve refractory cases, while Janus kinase inhibitors, B-cell-directed combinations, and engineered regulatory T-cell therapies show promise but require rigorous safety and translational validation. This review discusses major advances in immunopathogenesis, diagnostics, and therapeutics, comparing disease commonalities and distinctions to propose a framework for precision management. It envisions multi-omics phenotyping, artificial intelligence-assisted diagnostics, and pathway-directed immunomodulation to reduce blindness and enhance quality of life, bridging rheumatology and ophthalmology.
    Review • Journal
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL17A (Interleukin 17A)
    |
    Tepezza (teprotumumab-trbw)
    15d
    HAZEL 401: An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease (clinicaltrials.gov)
    P2, N=30, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    Electroacupuncture Improves the Learning and Memory by Modulating Hippocampal Glucose Metabolism through IGF1/IGF1R Signaling in Alzheimer's Disease. (PubMed, Adv Sci (Weinh))
    The glucose metabolic enhancement boosted tricarboxylic acid cycle activity and improved synaptic plasticity. Our findings establish a novel mechanism by which EA improves the learning and memory through the IGF1/IGF1R pathway, providing both theoretic and experimental support for the clinical application of EA in AD treatment.
    Journal
    |
    IGF1 (Insulin-like growth factor 1)
    20d
    The insulin receptor inhibitor BMS-754807 alleviates neuroinflammation and Alzheimer's disease pathologies across human cellular and mouse models. (PubMed, J Neuroinflammation)
    Taken together, our results suggest that BMS-754807 exerts anti-inflammatory and potential disease-modifying effects by attenuating LPS/Aβ/tau-evoked glial activation and reducing Aβ and tau pathologies in both human cellular and mouse models of neuroinflammation and AD. Furthermore, BMS-754807 administration improved specific domains of cognitive function in vivo. These findings support pharmacological inhibition of IGF-1R as a potential therapeutic approach for neuroinflammation-associated diseases including AD.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • IR (Insulin receptor) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    BMS-754807
    21d
    20230294.01: An Open-label, Rollover Study to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease (2025-523280-38-00)
    P1/2, N=2, Not yet recruiting, Amgen Inc.
    New P1/2 trial
    22d
    Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Tepezza (teprotumumab-trbw) • methylprednisolone sodium succinate